241 related articles for article (PubMed ID: 35471557)
1. Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment.
Kleinendorst SC; Oosterwijk E; Bussink J; Westdorp H; Konijnenberg MW; Heskamp S
Clin Cancer Res; 2022 Sep; 28(17):3652-3657. PubMed ID: 35471557
[TBL] [Abstract][Full Text] [Related]
2. Integrin α
Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
[TBL] [Abstract][Full Text] [Related]
3. Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic.
Bellavia MC; Patel RB; Anderson CJ
J Nucl Med; 2022 Nov; 63(11):1636-1641. PubMed ID: 36215570
[TBL] [Abstract][Full Text] [Related]
4. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.
Patel RB; Hernandez R; Carlson P; Grudzinski J; Bates AM; Jagodinsky JC; Erbe A; Marsh IR; Arthur I; Aluicio-Sarduy E; Sriramaneni RN; Jin WJ; Massey C; Rakhmilevich AL; Vail D; Engle JW; Le T; Kim K; Bednarz B; Sondel PM; Weichert J; Morris ZS
Sci Transl Med; 2021 Jul; 13(602):. PubMed ID: 34261797
[TBL] [Abstract][Full Text] [Related]
5. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma.
Choi J; Beaino W; Fecek RJ; Fabian KPL; Laymon CM; Kurland BF; Storkus WJ; Anderson CJ
J Nucl Med; 2018 Dec; 59(12):1843-1849. PubMed ID: 29959213
[TBL] [Abstract][Full Text] [Related]
6. Combination Strategies to Improve Targeted Radionuclide Therapy.
Chan TG; O'Neill E; Habjan C; Cornelissen B
J Nucl Med; 2020 Nov; 61(11):1544-1552. PubMed ID: 33037092
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy.
Rouanet J; Benboubker V; Akil H; Hennino A; Auzeloux P; Besse S; Pereira B; Delorme S; Mansard S; D'Incan M; Degoul F; Rouzaire PO
Cancer Immunol Immunother; 2020 Oct; 69(10):2075-2088. PubMed ID: 32447411
[TBL] [Abstract][Full Text] [Related]
8. Antitumor efficacy of
Potluri HK; Ferreira CA; Grudzinski J; Massey C; Aluicio-Sarduy E; Engle JW; Kwon O; Marsh IR; Bednarz BP; Hernandez R; Weichert JP; McNeel DG
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002185
[TBL] [Abstract][Full Text] [Related]
9. Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy.
Jagodinsky JC; Jin WJ; Bates AM; Hernandez R; Grudzinski JJ; Marsh IR; Chakravarty I; Arthur IS; Zangl LM; Brown RJ; Nystuen EJ; Emma SE; Kerr C; Carlson PM; Sriramaneni RN; Engle JW; Aluicio-Sarduy E; Barnhart TE; Le T; Kim K; Bednarz BP; Weichert JP; Patel RB; Morris ZS
Theranostics; 2021; 11(13):6120-6137. PubMed ID: 33995649
[No Abstract] [Full Text] [Related]
10. Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors.
Pouget JP; Chan TA; Galluzzi L; Constanzo J
Trends Cancer; 2023 Nov; 9(11):968-981. PubMed ID: 37612188
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Heidegger I; Necchi A; Pircher A; Tsaur I; Marra G; Kasivisvanathan V; Kretschmer A; Mathieu R; Ceci F; van den Bergh RCN; Thibault C; Tilki D; Valerio M; Surcel C; Gandaglia G;
Eur Urol Oncol; 2021 Oct; 4(5):745-754. PubMed ID: 33243663
[TBL] [Abstract][Full Text] [Related]
12. Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment.
Kerr CP; Grudzinski JJ; Nguyen TP; Hernandez R; Weichert JP; Morris ZS
Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678756
[TBL] [Abstract][Full Text] [Related]
13. Case Report:
Huang JW; Kuo CL; Wang LT; Ma KS; Huang WY; Liu FC; Yang KD; Yang BH
Front Immunol; 2021; 12():752563. PubMed ID: 35003064
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer.
Lu X; Wang J; Zhang T; Zhou Z; Deng L; Wang X; Wang W; Liu W; Tang W; Wang Z; Wang J; Jiang W; Bi N; Wang L
Front Immunol; 2022; 13():918787. PubMed ID: 35795657
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment.
Ruigrok EAM; Verkaik NS; de Blois E; de Ridder C; Stuurman D; Roobol SJ; Van Gent DC; de Jong M; Van Weerden WM; Nonnekens J
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887398
[TBL] [Abstract][Full Text] [Related]
16. Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma.
Li M; Liu D; Lee D; Cheng Y; Baumhover NJ; Marks BM; Sagastume EA; Ballas ZK; Johnson FL; Morris ZS; Schultz MK
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359580
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of radiotherapy and targeted radionuclide therapy for melanoma in preclinical mouse models: A combination treatments overview.
Lara-Vega I; Correa-Lara MVM; Vega-López A
Bull Cancer; 2023 Sep; 110(9):912-936. PubMed ID: 37277266
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
Lee L; Matulonis U
Gynecol Oncol; 2019 Jul; 154(1):236-245. PubMed ID: 30995960
[TBL] [Abstract][Full Text] [Related]
19. Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.
Yan Y; Kumar AB; Finnes H; Markovic SN; Park S; Dronca RS; Dong H
Front Immunol; 2018; 9():1739. PubMed ID: 30100909
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis.
Kim PH; Suh CH; Kim HS; Kim KW; Kim DY; Lee EQ; Aizer AA; Guenette JP; Huang RY
Korean J Radiol; 2021 Apr; 22(4):584-595. PubMed ID: 33289357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
